247. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five- year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis 2013 Apr;17(5 Suppl 1):S56-63. 248. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Obstet Gynecol 2013 Apr;121(4):829-846. 249. Kang WD, Kim CH, Cho MK, Kim JW, Cho HY, Kim YH, et al. HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB-IIA cervical cancer undergoing radical hysterectomy. Gynecol Oncol 2011 Jun 1;121(3):546-550. 250. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002 Nov 1;35(9):1127-1134. 251. D’Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008 Aug 1;48(4):491-499. 252. Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and highgrade anal intraepithelial neoplasia in Denmark, 1978–2008. Int J Cancer. 2012;130(5):1168–1173. 253. Jin F, Stein AN, Conway EL, Regan DG, Law M, Brotherton JM, et al. Trends in anal cancer in Australia, 1982-2005. Vaccine 2011 Mar 9;29(12):2322-2327. 254. Robinson D, Coupland V, Moller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers inSoutheast England. Br J Cancer. 2009;100(3):527–531. 255. Crowe E, Pandeya N, Brotherton JM et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:g1458. 256. Mesher,D, K.Soldan, R.Howell-Jones, K.Panwar, P.Manyenga, M. Jit, S.Beddows, O.N.Gill: Type- specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. J Clin Pathol. 2015 Feb;68(2):135-40. 257. Hariri S, Markowitz LE, Bennett NM, Niccolai LM, Schafer S, Bloch K, et al. Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012. Emerg Infect Dis 2015 Sep;21(9):1557-1561. 258. Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. Bmj-Brit Med J 2013;346:f2032. 259. Graham DM, Isaranuwatchai W, Habbous S, de Oliveira C, Liu G, Siu LL, et al. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. Cancer 2015 Jun 1;121(11):1785-1792. 260. Winer RL, Hughes JP, Feng Q, Xi LF, Lee SK, O’Reilly SF, et al. Prevalence and risk factors for oncogenic human papillomavirus infections in high- risk mid-adult women. Sex Transm Dis 2012 Nov;39(11):848-856. 261. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 2012; 307:693–703. 262. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294–301. 263. Beachler DC, D’Souza G, Sugar EA, Xiao W, Gillison ML. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis 2013 Jul 15;208(2):330-339. 264. Nyitray AG, Carvalho da Silva RJ, Baggio ML, Smith D, Abrahamsen M, Papenfuss M, et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis 2011 Dec 1;204(11):1711-1722. 265. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J 2015 Sep;34(9):983-991. 266. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep 2014 Jul 25;63(29):620-624.

xiv Contemporary Clinical Questions on HPV-Related Diseases and Vaccination

Made with